|
KMID : 0356820140300020090
|
|
Korean Journal of Head & Neck Oncology
2014 Volume.30 No. 2 p.90 ~ p.94
|
|
|
Trastuzumab in a Patient with Metastatic Salivary Duct Carcinoma : A Case Report
|
|
Gong Bong-Han
Lee Ji-Eun
Choi Sang-Su
Kim Yeon-Sil
Kim Min-Sik
Lee Youn-Soo
Lee Ji-Yeon
Hong Sook-Hyee
Kang Jin-Hyoung
|
|
|
Abstract
|
|
|
|
Salivary duct carcinoma(SDC) is rare malignancy, accounting for approximately 1-3% of all malignant salivary gland tumors. Systemic chemotherapy has been used for stage IV SDC, but there is no consensus on the standard treatment. SDC is histologically similar to ductal carcinoma of breast and often overexpress HER2/neu, hence HER2/neu targeted therapy could be one of treatment options. A 75-year-old Arabian man was diagnosed as SDC of right parotid gland with extensive metastases. He received oral 5-FU as palliative chemotherapy, but he was intolerable to oral chemotherapy due to severe oral mucositis. Considering immunohistochemical stain of tumor tissue showing strong positive for HER2/neu, we decided to administer an anti-HER2/neu antibody, trastuzumab. Follow-up CT scans before the third dose of trastuzumab demonstrated remarkable regression of multiple metastases as well as primary tumor. This case suggests that HER2/neu targeted therapy may be a potential therapeutic option for the SDC patient with overexpression of HER2/neu.
|
|
|
KEYWORD
|
|
|
Salivary duct carcinoma, HER2/neu, Trastuzumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|